Aegerion Pharmaceuticals Receives Positive European CHMP Opinion for LOJUXTA(TM) (lomitapide) to Treat Homozygous Familial Hypercholesterolemia (HoFH)

Aegerion Pharmaceuticals, Inc. (AEGR), a biopharmaceutical company dedicated to the development and commercialization of novel, life-altering therapies for patients with debilitating, often fatal, rare diseases, announced today that the European Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion with a unanimous vote recommending a marketing authorization for LOJUXTA(TM) (lomitapide) hard capsules. If approved, LOJUXTA will be indicated as an adjunct to a low-fat diet and other lipid-lowering medicinal products with or without low density lipoprotein (LDL) apheresis in adult patients with homozygous familial hypercholesterolemia (HoFH).

Published: 31 May 2013

Written by Editor

Valeant Pharmaceuticals International, Inc. To Acquire Bausch + Lomb For $8.7 Billion

Will Establish Valeant as a Global Leader in Eye Health as Well as Dermatology

Expected to Achieve Annual Cost Savings of at Least $800 Million

Immediately Accretive to Valeant's Cash EPS

Pro Forma for full year 2013, ~40% Accretive to Valeant's Cash EPS

Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) and Bausch + Lomb Holdings Incorporated, the global eye health company, today announced that they have entered into a definitive agreement under which Valeant will acquire Bausch + Lomb for $8.7 billion in cash.

Published: 27 May 2013

Written by Editor

TSX NYSE Healthcare M & A Up on News Interesting News

NPS Pharmaceuticals Prices Public Offering of Common Stock

NPS Pharmaceuticals, Inc. (NPSP) today announced the pricing of an underwritten public offering of 6,000,000 shares of its common stock at a price of $14.53 per share to the public. All of the shares are being sold by NPS. The gross proceeds to NPS from this offering are expected to be approximately $87.2 million, before deducting underwriting discounts and commissions, and other estimated offering expenses payable by NPS. The offering is expected to close on or about May 24, 2013, subject to the satisfaction of customary closing conditions.

J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC are acting as joint book-running managers for the offering. Canaccord Genuity Inc. and Leerink Swann LLC are acting as lead co-managers for the offering and Oppenheimer & Co. Inc. and Wedbush PacGrow Life Sciences are acting as co-managers for the offering.

Published: 22 May 2013

Written by Editor

Nasdaq Healthcare Up on News New Listing Interesting News

Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S.

Oramed Pharmaceuticals Inc. (ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that the United States Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug application(IND) for ORMD-0801, its oral insulin capsule.

"We are very pleased to have the FDA clearance to proceed," stated Nadav Kidron, CEO of Oramed. "The upcoming trial is a major milestone for Oramed and we look forward to continuing to progress ORMD-0801's clinical development in the US."

Published: 17 May 2013

Written by Editor

Nasdaq Healthcare Drill Results Up on News Interesting News

Theravance and Elan Enter Into a $1.0 Billion Royalty Participation Agreement

Theravance to receive $1.0 billion upfront payment upon closing; Elan to receive a 21% participation interest in potential future royalty payments associated with four respiratory programs

Theravance, Inc. (NASDAQ: THRX) and Elan Corporation, plc (NYSE: ELN) today announced that they have entered into a royalty participation agreement wherein Elan will purchase a participation interest in potential future royalty payments related to four respiratory programs partnered with GlaxoSmithKline plc (GSK): RELVAR™ ELLIPTA™/BREO™ ELLIPTA™, ANORO™ ELLIPTA™, MABA (Bifunctional Muscarinic Antagonist-Beta₂ Agonist) monotherapy (GSK961081, or MABA '081), and vilanterol (VI) monotherapy. Under the terms of the agreement, Elan will make a one-time cash payment of $1.0 billion to Theravance in exchange for a 21% participation interest in the potential future royalty payments from the four programs when, as and if received by Theravance.

Published: 13 May 2013

Written by Editor

Nasdaq Healthcare Project Updates Up on News Interesting News

Aegerion Pharmaceuticals ( AEGR )

Aegerion Pharmaceuticals Receives Positive European CHMP Opinion for LOJUXTA(TM) (lomitapide) to Treat Homozygous Familial Hypercholesterolemia (HoFH)

Valeant Pharmaceuticals International Inc ( VRX )

Valeant Pharmaceuticals International, Inc. To Acquire Bausch + Lomb For $8.7 Billion

NPS Pharmaceuticals Inc ( NPSP )

NPS Pharmaceuticals Prices Public Offering of Common Stock

Oramed Pharmaceuticals Inc ( ORMP )

Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S.

Theravance Inc ( THRX )

Theravance and Elan Enter Into a $1.0 Billion Royalty Participation Agreement